BC Cancer Agency

Running trials

• Recruiting

  A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

  NCT07549412· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

  NCT07360314· Phase 1· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease

  NCT05986318· Phase 2· David Palma· Source

• Recruiting

  Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

  NCT06345079· Phase 2· Australasian Gastro-Intestinal Trials Group· Source

• Recruiting

  CfDNA in Hereditary And High-risk Malignancies 2

  NCT06726642· University Health Network, Toronto· Source

• Active, not recruiting

  IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

  NCT05987332· Phase 2/3· IDEAYA Biosciences· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05083169· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

  NCT04566887· Phase 2· University Health Network, Toronto· Source

• Active, not recruiting

  A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing

  NCT06129084· Bernie Eigl· Source

• Recruiting

  Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

  NCT04335292· Phase 2· Mark Vincent· Source

• Active, not recruiting

  GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma

  NCT04472910· University Health Network, Toronto· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

  NCT03972488· Phase 3· Advanced Accelerator Applications· Source

• Active, not recruiting

  Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

  NCT04164901· Phase 3· Institut de Recherches Internationales Servier· Source

• Active, not recruiting

  Cell-free DNA in Hereditary And High-Risk Malignancies 1

  NCT04261972· University Health Network, Toronto· Source

• Recruiting

  International Registry for Men With Advanced Prostate Cancer (IRONMAN)

  NCT03151629· Prostate Cancer Clinical Trials Consortium· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Gastric and oesophageal cancer2 recruiting
• Ovarian cancer2 recruiting
• Pancreatic cancer2 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Head and neck cancer1 recruiting
• Neuroendocrine tumours1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Recruiting

  A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

  NCT05379595· Phase 1/2· Janssen Research & Development, LLC· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Terminated

  An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

  NCT05011058· Phase 2· Viracta Therapeutics, Inc.· Source

• Completed

  Pancreatic Adenocarcinoma Signature Stratification for Treatment

  NCT04469556· Phase 2· University Health Network, Toronto· Source

• Completed

  A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

  NCT04397276· Phase 1· Janssen Research & Development, LLC· Source

• Terminated

  Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome

  NCT03031821· Phase 3· Canadian Urologic Oncology Group· Source

• Completed

  A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

  NCT02632448· Phase 1/2· Esperas Pharma Inc.· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Kidney cancer25 works · 0 trials
• Hodgkin lymphoma18 works · 0 trials
• Diffuse large B-cell lymphoma17 works · 1 trial
• Follicular lymphoma7 works · 0 trials